GGrantIndex
Sort

82,697 grants matching vaccine development

Optimizing the Immunogenicity of MVA-Based AIDS Vaccines

$4,202,132
Emory University · U19 · FY2005 · AI

cGMP Manufacture, Fill-Finish, Release, and Stability Testing of a Nanoparticle Based HIV Envelope Containing Vaccine

$4,199,938
Timothy Fouts · Advanced Bioscience Laboratories, Inc. · N01 · FY2021 · AI

Immunologic strategies to prevent congenital cytomegalovirus transmission and disease in rhesus monkeys

$4,199,924
Sallie R. Permar · Weill Medical Coll Of Cornell Univ · P01 · FY2024 · AI

DEVELOPMENT OF A NOVEL CELL-BASED, LIVE INFLUENZA VACCINE WITH UNIVERSAL ATTRIBUTES

$4,198,890
Flugen Inc · · FY2019 · Department of the Army

Developing Immunogens to Elicit Broadly Neutralizing anti-HIV-1 Antibodies

$4,197,323
Pamela J Bjorkman · California Institute Of Technology · P01 · FY2024 · AI

Cancer Immunotherapy

$4,195,237
James L. Gulley · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA

Harvard University Center for AIDS Research

$4,195,217
Bruce D Walker · Harvard University · P30 · FY2012 · AI

Development And Production Of A Multiclade HIV-1 DNA Plasmid Vaccine

$4,188,372
Kimberly Wallace · National Institute Of Allergy And Infectious Diseases · Z01 · FY2008 · AI

Optimization Of HIV Specific Immune Responses In Vivo

$4,186,577
Robert A Seder · National Institute Of Allergy And Infectious Diseases · ZIA · FY2012 · AI

Optimization Of HIV Specific Immune Responses In Vivo

$4,186,577
Robert A Seder · National Institute Of Allergy And Infectious Diseases · ZIA · FY2015 · AI

Optimization Of HIV Specific Immune Responses In Vivo

$4,186,577
Robert A Seder · National Institute Of Allergy And Infectious Diseases · ZIA · FY2014 · AI

Optimization Of HIV Specific Immune Responses In Vivo

$4,186,577
Robert A Seder · National Institute Of Allergy And Infectious Diseases · ZIA · FY2013 · AI

DEVELOPMENT OF ANTHRAX VACCINE FORMULATI0N

$4,181,877
Laurence Lemiale · Emergent Product Development Gaithersbur · N01 · FY2016 · AI

Immune Reconstitution

$4,179,106
Ronald E. Gress · Basic Sciences · Z01 · FY2007 · CA

SHIV Env-antibody coevolution as a molecular guide to HIV-1 V3 glycan targeted vaccine design

$4,178,808
George M Shaw · University Of Pennsylvania · P01 · FY2022 · AI

IGF::OT::IGF NIAID Preclinical Development Support- cGMP Manufacturing of PGT121 and PGDM1400 Antibodies

$4,174,500
John Mascola · Advanced Bioscience Laboratories, Inc. · N01 · FY2018 · AI

Targeting mTOR and CD40 Pathways for Adjuvanting HIV Vaccines

$4,170,549
Rama Rao Amara · Emory University · P01 · FY2011 · AI

NIA AD/ADRD Health Care Systems Research Collaboratory

$4,168,993
Vincent Mor · Brown University · U54 · FY2021 · AG

COVID-19: NIAID Clinical Research Support Services (CRSS)

$4,167,596
Bambra Strokes · Ppd Development Lp · N01 · FY2022 · AI

FEND for TB

$4,167,230
Jerrold J. Ellner · Rbhs-New Jersey Medical School · U01 · FY2022 · AI

Prevention Research Center: Parenting Among Women Who Are Opioid Users

$4,166,575
Leslie Diane Leve · University Of Oregon · P50 · FY2020 · DA

Infectious Diseases Fellowship Program

$4,161,584
Christa Zerbe · National Institute Of Allergy And Infectious Diseases · ZIE · FY2024 · AI

ARRA: H1N1 Influenza Disease Modeling and Transmission

$4,154,469
Heinrich Feldmann · National Institute Of Allergy And Infectious Diseases · ZIA · FY2010 · AI

UAB Center for AIDS Research

$4,153,930
Michael S. Saag · University Of Alabama At Birmingham · P30 · FY2013 · AI

New England Regional Center of Excellence for Biodefense

$4,152,399
Harvard University (Medical School) · U54 · FY2003 · AI